# US 2021/0330677 A1 · Pkc inhibitors for the treatment of septic cholestasis with ctm targeting

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330677 A1
- Document ID: US20210330677A1
- Status: Published application
- Kind: A1
- Application number: 17/271,422
- Filed: 2019-08-26
- Published: 2021-10-28
- Earliest claimed: 2018-08-27
- Assignees: Smartdyelivery GmbH
- Applicants: Smartdyelivery GmbH
- Inventors: Christoph ENZENSPERGER; Marc LEHMANN
- Web page: https://patentgrep.com/patent/US20210330677A1

## CPC

- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/133: having hydroxy groups, e.g. sphingosine
- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61K 31/365: Lactones
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/52: Purines, e.g. adenine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/585: containing lactone rings, e.g. oxandrolone, bufalin
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 38/1767: {from invertebrates}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/593: {Polyesters, e.g. PLGA or polylactide-co-glycolide}
- A61K 47/6925: {the form being a microcapsule, nanocapsule, microbubble or nanobubble}
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one carbohydrate targeting moiety and at least one polymer and/or at least one lipid and/or at least one virus-like particle.

## Claims

### Claim at position 1

-13. (canceled)

### Claim 14

A nanostructured delivery system, comprising:
an inhibitor of a protein kinase C (PKC) signaling pathway;
at least one carbohydrate targeting moiety; and
a carrier,
wherein the nanostructured delivery system is adapted for treating septic cholestasis by lowering or inhibiting PKC in liver cells.

### Claim 15 (depends on 14)

The nanostructured delivery system of claim 14, wherein the carbohydrate targeting moiety is covalently attached to the carrier.

### Claim 16 (depends on 15)

The nanostructured delivery system of claim 15, wherein the inhibitor of the PKC signaling pathway is encapsulated by the carrier.

### Claim 17 (depends on 14)

The nanostructured delivery system of claim 14, wherein the inhibitor of the PKC signaling pathway is covalently attached to the carbohydrate targeting moiety or to the carrier.

### Claim 18 (depends on 14)

The nanostructured delivery system of claim 14, wherein the at least one carbohydrate targeting moiety is selected from the group of N-acetyl-galactosamine (GalNAc), galactose, lactose, mannose, glucosamine, asialofetuin, pullulan, arabinogalactan, glycyrrhizin, glycyrrhetinic acid, or any derivative thereof.

### Claim 19 (depends on 14)

The nanostructured delivery system of claim 14, wherein the at least one carbohydrate targeting moiety is adapted to bind to a recognizing unit located on the liver.

### Claim 20 (depends on 19)

The nanostructured delivery system of claim 19, wherein the recognizing unit is a receptor.

### Claim 21 (depends on 20)

The nanostructured delivery system of claim 20, wherein the receptor is a lectin, an asialoglycoprotein receptor (ASGPR) or an aka Ashwell-Morell receptor.

### Claim 22 (depends on 14)

The nanostructured delivery system of claim 14, wherein the inhibitor of the PKC signaling pathway is selected from the group of a PKC inhibitor, a PI3 kinase inhibitor, a MAPK inhibitor, a PLC inhibitor, a DAG level reducing agent, siRNA, shRNA, miRNA, a modified oligo analogue, an antisense construct, or RNAse H.

### Claim 23 (depends on 22)

The nanostructured delivery system of claim 22, wherein the inhibitor of the PKC signaling pathway is selected from the group of a bisindolylmaleimide, a staurosporine, a midostaurin, UCN-01, sotrastaurin, enzastaurin, ruboxistaurine, tivantinib, enzastaurin, Go 6983, K252a, ANA-12, lestaurtinib, stauprimide, CEP-701, Arcyriaflavin a, or Bisindolylmaleimids 1-XII aka BIM 1-XII.

### Claim 24 (depends on 22)

The nanostructured delivery system of claim 22, wherein the inhibitor of the PKC signaling pathway is a PI3 kinase inhibitor, the PI3 kinase inhibitor being selected from the group of copanlisib, idelalisib, wortmannin derivatives, bryostain derivatives, taselisib, omipalisib, AS605240, GSK1059615, buparlisib, alpelisib, pictilisib, serabilisib, dactolisib, dihydrosphingosine, calphostin C, or melittin.

### Claim 25 (depends on 14)

The nanostructured delivery system of claim 14, wherein the inhibitor of the PKC signaling pathway directly or indirectly inhibits or reduces an activity of PKC or PKC subtypes.

### Claim 26 (depends on 14)

The nanostructured delivery system of claim 14, wherein the carrier includes at least one polymer, or at least one lipid, or at least one virus-like particle, or any combination thereof.

### Claim 27 (depends on 26)

The nanostructured delivery system of claim 26, wherein the carrier includes at least one polymer, the at least one polymer being an organic polymer, an inorganic polymer, a hydrophobic polymer, a hydrophilic polymer, an amphiphilic polymer, an anionic polymer, a cationic polymer, or any combination thereof.

### Claim 28 (depends on 27)

The nanostructured delivery system of claim 27, wherein the at least one polymer is selected from the group of a polyester, a polyacrylate, a polystyrene, a polyamide, a polyurethane, a polyacrylonitrile, a polytetrafluoroethylene, a silicone, a polyethylene glycol, a polyethylene oxide, a polyoxazoline, a polysaccharide, or any copolymer thereof, or any combination thereof.

### Claim 29 (depends on 27)

The nanostructured delivery system of claim 27, wherein the at least one polymer is selected from the group of PLGA, PLA, PCL, PGA, PDMAEMA, PMMA, PMAA, PEI, PEtOx, PEG, HPMA, APMA, PVP, hydrolyzed PVP, or any combination thereof.

### Claim 30 (depends on 26)

The nanostructured delivery system of claim 26, wherein the carrier includes at least one lipid, the at least one lipid being selected from the group of a saturated fatty acid, an unsaturated fatty acid, a cholesterol derivative, a phospholipid, a sphingolipid, a lipoprotein, a glycolipid, or any combination thereof.

### Claim 31 (depends on 26)

The nanostructured delivery system of claim 26, wherein the carrier includes at least one virus-like particle, the at least one virus-like particle being derived from a virus selected from the group of Bacteriophage MS2, Bacteriophage Ob, Enterobacteria phage P22, Cowpea mosaic virus (CPMV) Cowpea Chlorotic Mottle Virus (CCMV), hepatitis B virus carries (HBVc), or Adeno associated virus (AAV).

### Claim 32 (depends on 14)

The nanostrucured delivery system of claim 14, wherein the carbohydrate targeting moiety is a multivalent construct.

### Claim 33 (depends on 14)

The nanostructured delivery system of claim 14, wherein the inhibitor of the PKC signaling pathway includes a PI3-kinase inhibitor, the at least one carbohydrate targeting moiety is a trivalent construct, and the carrier is a nanostructured polymer.
